Graft Versus Host Disease
Conditions
Keywords
HSCT, AGVHD, Myeloablative, Allogeneic, Hematopoietic, Stem, Cell, Transplantation
Brief summary
The objectives of this study are as follows: To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine if IV administration of opebacan is associated with changes in biological markers for inflammation To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD
Detailed description
IV infusion of opebacan to replace endogenous BPI during the peritransplant period will result in the reduction of LPS-induced inflammatory sequelae, in particular aGvHD, in patients undergoing allogeneic HSCT. The rationale for using opebacan in patients undergoing myeloablative regimens and HSCT is based on the following: Endotoxemia has been demonstrated to play a central pathophysiologic role as a trigger of aGvHD in animal models. Endotoxemia following HSCT is associated with inflammatory conditions (such as inflammatory cytokine release) that have been demonstrated in humans to be associated with organ damage and increased morbidity and mortality. Endotoxemia and LBP elevation have been demonstrated in humans undergoing ablative HSCT. Chemotherapy-induced neutropenia results in a deficiency of endogenous BPI levels. The timing of the endotoxemic insult is predictable (i.e., subsequent to myeloablative chemotherapy and radiotherapy). The return to normal neutrophil levels is not immediate and takes one week to several weeks. Well established laboratory techniques for surrogate markers related to LPS presence and its activities can facilitate the evaluation of molecules designed to inhibit or antagonize LPS and its effects. The objectives of this study are as follows: To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine if IV administration of opebacan is associated with changes in biological markers for inflammation To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD
Interventions
DRUGOpebacan
4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
Sponsors
XOMA (US) LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age \<= 60 and undergoing allogeneic HSCT * Life expectancy \> 8 weeks * Scheduled for treatment with a conditioning regimen intended to be myeloablative * Female subjects of child-bearing age must have a negative urine pregnancy test. Sexually active male and female subjects of reproductive age must be using a form of contraception considered effective and medically acceptable by the Investigator.
Exclusion criteria
* Cumulative lifetime exposure of \> 300 mg/M2 of anthracycline (expressed as doxorubicin equivalent dose) or receipt of anthracycline within 180 days prior to initiating conditioning for HSCT * Active infection * Prophylactic antibacterial antibiotics. * Positive for HIV, HTLV-I, or HTLV-II * Any prior stem cell transplant * Prior history of CHF * Cord blood is the source of a subject's transplanted cells.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to engraftment | 100 days |
| Inflammatory markers | 100 days |
| Inflammatory states | 100 days |
| Transplant-related complications | 100 days |
| The pharmacokinetics of opebacan | 100 days |
Countries
United States
Outcome results
None listed